Albert Do
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Albert Do has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Joseph Kartaik Lim
Section of Digestive Diseases and Yale Liver Center, Yale School of Medicine, New Haven, Connecticut, USA
6 shared publications - Ysabel C. Ilagan-Ying
Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, USA
3 shared publications - Aaron Yeoh
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2 shared publications - Amy C. Justice
VA Connecticut Healthcare System , West Haven, Connecticut
2 shared publications - Denise Esserman
Department of Biostatistics; Yale School of Public Health; New Haven, CT, USA
2 shared publications Janet P. Tate
Department of Internal Medicine, Yale University School of Medicine, New Haven, USA
2 shared publications
Latest Publications
- 13 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1841-1848
Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
INTRODUCTION: Hepatic steatosis is highly prevalent in people living with HIV. It remains unclear whether HIV in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with greater risks of liver disease progression and cardiovascular disease (CVD). We aim to evaluate the impact of HIV infection on risks of liver and CVD outcomes among US Veterans with MASLD. METHODS: Using national Veterans Administration data from 2010 to 2022, we created a propensity score-matched cohort of MASLD patients with vs without HIV. Primary outcomes were incidence of cirrhosis and hepatocellular carcinoma (HCC) among patients with vs without HIV and patients with MASLD-HIV on antiretroviral therapy (ART) vs not on ART. Secondary outcomes included incidence of major adverse cardiovascular events and overall survival. RESULTS: The propensity-matched cohort included 920 MASLD patients with HIV and 920 MASLD patients without HIV and was similar in demographics and comorbidities. Compared with MASLD patients without HIV, incidences of cirrhosis and HCC were similar among MASLD with HIV. Compared with MASLD patients without HIV, incidence of major adverse cardiovascular event was higher among MASLD patients with HIV (5.18 vs 4.48 per 100 person-years, P = 0.03). Overall 5-year survival was significantly lower among MASLD patients with HIV and even lower among those not on ART. DISCUSSION: Among US Veterans with MASLD, concurrent HIV infection, and particularly not being on ART, is associated with greater risks of CVD and decreased overall survival. No differences in risks of cirrhosis or HCC were observed.
- 13 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1841-1848
Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
INTRODUCTION: Hepatic steatosis is highly prevalent in people living with HIV. It remains unclear whether HIV in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with greater risks of liver disease progression and cardiovascular disease (CVD). We aim to evaluate the impact of HIV infection on risks of liver and CVD outcomes among US Veterans with MASLD. METHODS: Using national Veterans Administration data from 2010 to 2022, we created a propensity score-matched cohort of MASLD patients with vs without HIV. Primary outcomes were incidence of cirrhosis and hepatocellular carcinoma (HCC) among patients with vs without HIV and patients with MASLD-HIV on antiretroviral therapy (ART) vs not on ART. Secondary outcomes included incidence of major adverse cardiovascular events and overall survival. RESULTS: The propensity-matched cohort included 920 MASLD patients with HIV and 920 MASLD patients without HIV and was similar in demographics and comorbidities. Compared with MASLD patients without HIV, incidences of cirrhosis and HCC were similar among MASLD with HIV. Compared with MASLD patients without HIV, incidence of major adverse cardiovascular event was higher among MASLD patients with HIV (5.18 vs 4.48 per 100 person-years, P = 0.03). Overall 5-year survival was significantly lower among MASLD patients with HIV and even lower among those not on ART. DISCUSSION: Among US Veterans with MASLD, concurrent HIV infection, and particularly not being on ART, is associated with greater risks of CVD and decreased overall survival. No differences in risks of cirrhosis or HCC were observed.
- Open Access
Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Introduction: The independent effect of exercise on liver histology in non-alcoholic fatty liver disease (NAFLD) remains unclear. As such, we conducted a systematic review and meta-analysis of the effect of exercise alone on histological endpoints in biopsy-proven NAFLD. Materials and Methods: A systematic literature search was conducted to include controlled clinical trials investigating the effect of exercise alone on liver histology in biopsy-proven NAFLD. Meta-analysis was conducted for histological outcomes with available data from a minimum of three studies. Pooled estimates of the effect of exercise on histological endpoints were calculated using random-effects models. Results: We identified three controlled clinical trials that assessed the independent effect of exercise on histological outcomes in patients with biopsy-proven NAFLD. The studies consisted of 72 total participants, including 40 subjects in the exercise intervention and 32 individuals in the comparison group. Meta-analysis showed that exercise did not significantly improve Brunt grade, NAFLD activity score, and fibrosis in NAFLD. Discussion: Exercise alone may not lead to significant histopathological improvement in NAFLD. Future well-powered randomized controlled trials are needed to better characterize the impact of exercise on histological outcomes and clinical endpoints.
Open AccessExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Introduction: The independent effect of exercise on liver histology in non-alcoholic fatty liver disease (NAFLD) remains unclear. As such, we conducted a systematic review and meta-analysis of the effect of exercise alone on histological endpoints in biopsy-proven NAFLD. Materials and Methods: A systematic literature search was conducted to include controlled clinical trials investigating the effect of exercise alone on liver histology in biopsy-proven NAFLD. Meta-analysis was conducted for histological outcomes with available data from a minimum of three studies. Pooled estimates of the effect of exercise on histological endpoints were calculated using random-effects models. Results: We identified three controlled clinical trials that assessed the independent effect of exercise on histological outcomes in patients with biopsy-proven NAFLD. The studies consisted of 72 total participants, including 40 subjects in the exercise intervention and 32 individuals in the comparison group. Meta-analysis showed that exercise did not significantly improve Brunt grade, NAFLD activity score, and fibrosis in NAFLD. Discussion: Exercise alone may not lead to significant histopathological improvement in NAFLD. Future well-powered randomized controlled trials are needed to better characterize the impact of exercise on histological outcomes and clinical endpoints.
- 13 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (1) , 6-7
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI
An abstract is unavailable. This article is available as a PDF only.
- 13 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (1) , 6-7
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 21 January 2023
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (3) , 1-4
Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine
- 21 January 2023
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (3) , 1-4
Open AccessBroadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine
- Open Access
- 14 November 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (3) , 563-570
Outcomes of Patients with Opioid-Related Diagnoses in Acute Coronary Syndrome: a National Inpatient Sample-Based Analysis
Background Acute coronary syndrome (ACS) and opioid use are both major causes of morbidity and mortality globally. Although epidemiological studies point to increased risk of ACS in opioid users, in-hospital management and outcomes are unknown for this population when presenting with ACS. We sought to determine whether there are differences for in-hospital outcomes and management of ACS for those with and without opioid-related diagnoses (ORD). Methods and Results From the National Inpatient Sample database, we extracted patients hospitalized between 2012 and 2016 for ACS. The primary independent variable was ORD by International Classification of Diseases, 9th and 10th Revision, codes. The primary outcome was in-hospital mortality; secondary outcomes were cardiac arrest, receipt of angiogram, and percutaneous coronary intervention (PCI). Statistical comparisons were performed using χ2 test and Student’s t test. Multivariable logistic regression was performed to determine the independent association between ORD and outcomes of interest. Among the estimated 5.8 million admissions for ACS, the proportion of patients with ORD increased over the study period (p for trend < 0.01). Compared to patients without ORD presenting with ACS, patients with ORD were younger with fewer cardiovascular risk factors. Yet, in-hospital mortality was higher in patients with ORD presenting with ACS (AOR 1.36, 95% CI 1.26–1.48). Patients with ORD were more likely to experience in-hospital cardiac arrest (AOR 1.42, 95% CI 1.23–1.63) and less likely to undergo angiogram (AOR 0.42, 95% CI 0.38–0.45) or PCI (AOR 0.30, 95% CI 0.28–0.32). Conclusion Despite evidence of increased risk of mortality and cardiac arrest, patients with ORD admitted for ACS are less likely to receive ACS management.
- 14 November 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (3) , 563-570
Open AccessOutcomes of Patients with Opioid-Related Diagnoses in Acute Coronary Syndrome: a National Inpatient Sample-Based Analysis
Background Acute coronary syndrome (ACS) and opioid use are both major causes of morbidity and mortality globally. Although epidemiological studies point to increased risk of ACS in opioid users, in-hospital management and outcomes are unknown for this population when presenting with ACS. We sought to determine whether there are differences for in-hospital outcomes and management of ACS for those with and without opioid-related diagnoses (ORD). Methods and Results From the National Inpatient Sample database, we extracted patients hospitalized between 2012 and 2016 for ACS. The primary independent variable was ORD by International Classification of Diseases, 9th and 10th Revision, codes. The primary outcome was in-hospital mortality; secondary outcomes were cardiac arrest, receipt of angiogram, and percutaneous coronary intervention (PCI). Statistical comparisons were performed using χ2 test and Student’s t test. Multivariable logistic regression was performed to determine the independent association between ORD and outcomes of interest. Among the estimated 5.8 million admissions for ACS, the proportion of patients with ORD increased over the study period (p for trend < 0.01). Compared to patients without ORD presenting with ACS, patients with ORD were younger with fewer cardiovascular risk factors. Yet, in-hospital mortality was higher in patients with ORD presenting with ACS (AOR 1.36, 95% CI 1.26–1.48). Patients with ORD were more likely to experience in-hospital cardiac arrest (AOR 1.42, 95% CI 1.23–1.63) and less likely to undergo angiogram (AOR 0.42, 95% CI 0.38–0.45) or PCI (AOR 0.30, 95% CI 0.28–0.32). Conclusion Despite evidence of increased risk of mortality and cardiac arrest, patients with ORD admitted for ACS are less likely to receive ACS management.
- 23 May 2022
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 19 (6) , 227-233
Clinical Phenotyping and the Application of Precision Medicine in MAFLD
Content available: Audio Recording.
- 23 May 2022
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 19 (6) , 227-233
Clinical Phenotyping and the Application of Precision Medicine in MAFLD
Content available: Audio Recording.
- 1 May 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (6) , S-910-910
921 WEIGHING THE OPTIONS: ATTITUDES AND PERCEPTIONS OF BARIATRIC SURGERY AMONGST PROVIDERS BASED ON REFERRAL PATTERNS
- 1 May 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (6) , S-910-910
921 WEIGHING THE OPTIONS: ATTITUDES AND PERCEPTIONS OF BARIATRIC SURGERY AMONGST PROVIDERS BASED ON REFERRAL PATTERNS
- 1 January 2021
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 50 (1) , 74-84
Endoscopic Retrograde Cholangiopancreatography: Deciphering the Black and White
- 1 January 2021
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 50 (1) , 74-84
Endoscopic Retrograde Cholangiopancreatography: Deciphering the Black and White
- 22 October 2020
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 16 (2) , 125-134
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
The growing prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and its association with obesity as a metabolic disease contributes to harmful outcomes a...
- 22 October 2020
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 16 (2) , 125-134
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
The growing prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and its association with obesity as a metabolic disease contributes to harmful outcomes a...